Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
M&A remains ‘top priority’ for pharmas in face of tariff threat
Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being.
James Waldron
Apr 25, 2025 10:41am
Tariffs make M&A decisions 'more difficult,' says Roche CEO
Apr 24, 2025 4:40am
Ypsomed sells diabetes business to focus on GLP-1 self-injectors
Apr 23, 2025 6:20am
Alis wants to free capital 'trapped' at struggling biotechs
Apr 18, 2025 9:45am
RadNet to absorb mammography AI developer iCad in $103M deal
Apr 16, 2025 2:05pm
Private equity firm acquires CRO CenExel
Apr 15, 2025 12:50pm
